The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R
Open accessAbstract
The function of urokinase and its receptor is essential for cell migration in pathological conditions, as shown by the analysis of knockout mice phenotypes. How a protease of a fibrinolytic pathway can induce migration is not understood and no link between this protease and migration-promoting G protein-coupled receptors has been described. We now show that FPRL1/LXA4R, a G protein-coupled receptor for a number of polypeptides and for the endogenous lipoxin A4 (LXA4), is the link between urokinase-type plasminogen activator (uPA) and migration as it directly interacts with an activated, soluble, cleaved form of uPA receptor (uPAR) (D2D3 88–274 ) to induce chemotaxis. In this article we show that ( i ) both uPAR and FPRL1/LXA4R are necessary for the chemotactic activity of uPA whereas FPRL1/LXA4R is sufficient to mediate D2D3 88–274 -induced cell migration. ( ii ) Inhibition or desensitization of FPRL1/LXA4R by antibodies or specific ligands specifically prevents chemotaxis induced by D2D3 88–274 in THP-1 cells and human peripheral blood monocytes. ( iii ) Desensitization of FPRL1/LXA4R prevents the activation of tyrosine kinase Hck induced by D2D3 88–274 . ( iv ) D2D3 88–274 directly binds to FPRL1/LXA4R and is competed by two specific FPRL1/LXA4R agonists, the synthetic MMK-1 peptide and a stable analog of LXA4. Thus, a naturally produced cleaved form of uPAR is a unique endogenous chemotactic agonist for FPRL1/LXA4R receptor and its activity can be antagonized by specific ligands. These results provide the first direct link, to our knowledge, between the fibrinolytic machinery and the inflammatory response, demonstrating that uPA-derived peptide fragments can activate a specific chemotactic receptor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of Integrin Function by the Urokinase Receptor
Wei, Y., Lukashev, M., Simon, D. I., Bodary, S. C., Rosenberg, S., Doyle, M. V., & Chapman, H. A. (1996) · Science · doi:10.1126/science.273.5281.1551 · Cited by 727
Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration
Chapman, H. A. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80126-3 · Cited by 464
Deng, G., Curriden, S. A., Wang, S., Rosenberg, S., & Loskutoff, D. J. (1996) · The Journal of cell biology · doi:10.1083/jcb.134.6.1563 · Cited by 448
Ossowski, L., & Aguirre-Ghiso, J. A. (2000) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00140-x · Cited by 380
Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation
Johnsen, M., Lund, L. R., Rømer, J., Almholt, K., & Danø, K. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80044-6 · Cited by 356
Chemokine receptors: Structure, function and role in microbial pathogenesis
Murphy, P. (1996) · Cytokine & Growth Factor Reviews · doi:10.1016/1359-6101(96)00009-3 · Cited by 320
Resnati, M., Guttinger, M., Valcamonica, S., Sidenius, N., Blasi, F., & Fazioli, F. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00502.x · Cited by 299
Self-citationPlasma Urokinase Receptor Levels in Patients With Colorectal Cancer: Relationship to Prognosis
Stephens, R. W. (1999) · Journal of the National Cancer Institute · doi:10.1093/jnci/91.10.869 · Cited by 279
Amyloid β42Activates a G-Protein-Coupled Chemoattractant Receptor, FPR-Like-1
Le, Y., Gong, W., Tiffany, H. L., Tumanov, A., Nedospasov, S., Shen, W., Dunlop, N. M., Gao, J.-L., Murphy, P. M., Oppenheim, J. J., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-j0003.2001 · Cited by 270
Self-citationChemoattractant Receptor Cross-desensitization
Ali, H., Richardson, R. M., Haribabu, B., & Snyderman, R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6027 · Cited by 269
Cited by
uPAR: a versatile signalling orchestrator
Blasi, F., & Carmeliet, P. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm977 · Cited by 1,223
Self-citationRegulation of cell signalling by uPAR
Smith, H. W., & Marshall, C. J. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2821 · Cited by 960
Molecular mechanisms of glioma invasiveness: the role of proteases
Rao, J. S. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1121 · Cited by 847
Ye, R. D., Boulay, F., Wang, J. M., Dahlgren, C., Gerard, C., Parmentier, M., Serhan, C. N., & Murphy, P. M. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001578 · Cited by 764
Self-citationFormyl-peptide receptors revisited
LE, Y., MURPHY, P., & WANG, J. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02316-5 · Cited by 597
Self-citationThe Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion
Bellail, A. C., Hunter, S. B., Brat, D. J., Tan, C., & Van Meir, E. G. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.01.013 · Cited by 526
Mahmood, N., Mihalcioiu, C., & Rabbani, S. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00024 · Cited by 478
“The suPAR can activate the G protein-coupled chemotactic receptor FPRL1/LXA4R by functioning as an endogenous chemotactic agonist (64).”
BackgroundThe Lipoxin Receptor ALX: Potent Ligand-Specific and Stereoselective Actions in Vivo
Chiang, N., Serhan, C. N., Dahlén, S.-E., Drazen, J. M., Hay, D. W. P., Rovati, G. E., Shimizu, T., Yokomizo, T., & Brink, C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.4 · Cited by 464
Self-citationMIGEOTTE, I., COMMUNI, D., & PARMENTIER, M. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2006.09.009 · Cited by 457
Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead
van Hinsbergh, V. W. M., & Koolwijk, P. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvm102 · Cited by 420
Sidenius, N., & Blasi, F. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023099415940 · Cited by 368
Self-citationMulti-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A4
Levy, B. D., De Sanctis, G. T., Devchand, P. R., Kim, E., Ackerman, K., Schmidt, B. A., Szczeklik, W., Drazen, J. M., & Serhan, C. N. (2002) · Nature Medicine · doi:10.1038/nm748 · Cited by 352
Self-citationImmunomodulatory Activities of Small Host Defense Peptides
Bowdish, D. M. E., Davidson, D. J., Scott, M. G., & Hancock, R. E. W. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.5.1727-1732.2005 · Cited by 316
uPA and uPAR in fibrinolysis, immunity and pathology
Mondino, A., & Blasi, F. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.06.004 · Cited by 309
Self-citationDufton, N., Hannon, R., Brancaleone, V., Dalli, J., Patel, H. B., Gray, M., D’Acquisto, F., Buckingham, J. C., Perretti, M., & Flower, R. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903526 · Cited by 302
International Union of Pharmacology XXXVII. Nomenclature for Leukotriene and Lipoxin Receptors
Brink, C., Dahlén, S.-E., Drazen, J., Evans, J. F., Hay, D. W. P., Nicosia, S., Serhan, C. N., Shimizu, T., & Yokomizo, T. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.1.8 · Cited by 286
Self-citationPulukuri, S. M., Gondi, C. S., Lakka, S. S., Jutla, A., Estes, N., Gujrati, M., & Rao, J. S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503111200 · Cited by 285
RetractedThe Formyl Peptide Receptors: Diversity of Ligands and Mechanism for Recognition
He, H.-Q., & Ye, R. (2017) · Molecules · doi:10.3390/molecules22030455 · Cited by 279
The urokinase receptor: Focused cell surface proteolysis, cell adhesion and signaling
Blasi, F., & Sidenius, N. (2010) · FEBS Letters · doi:10.1016/j.febslet.2009.12.039 · Cited by 258
Self-citationuPAR induces epithelial–mesenchymal transition in hypoxic breast cancer cells
Lester, R. D., Jo, M., Montel, V., Takimoto, S., & Gonias, S. L. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200701092 · Cited by 253
Anti-inflammatory circuitry: Lipoxin, aspirin-triggered lipoxins and their receptor ALX
Chiang, N., Arita, M., & Serhan, C. N. (2005) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2005.05.003 · Cited by 239
Self-citationSu, S.-C., Lin, C.-W., Yang, W.-E., Fan, W.-L., & Yang, S.-F. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1113260 · Cited by 145
Role of Urokinase Receptor in Tumor Progression and Development
Noh, H., Hong, S., & Huang, S. (2013) · Theranostics · doi:10.7150/thno.4218 · Cited by 129
Metrangolo, V., Ploug, M., & Engelholm, L. H. (2021) · Cancers · doi:10.3390/cancers13215376 · Cited by 44
Metadata
- Authors
- Resnati, M., Pallavicini, I., Wang, J. M., Oppenheim, J., Serhan, C. N., Romano, M., & Blasi, F.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2002-01-29
- Volume
- 99
- Issue
- 3
- Pages
- 1359-1364
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2140690574
- Cited by
- 360
- References
- 27
- FWCI
- 11.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.